Research programme: PDGFR tyrosine kinase inhibitors - Johnson & Johnson

Drug Profile

Research programme: PDGFR tyrosine kinase inhibitors - Johnson & Johnson

Alternative Names: JNJ-10198409; Research programme: platelet-derived growth factor receptor tyrosine kinase inhibitors - Johnson & Johnson; RWJ-540973

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Johnson & Johnson Pharmaceutical Research & Development
  • Class Pyrazoles
  • Mechanism of Action Angiogenesis inhibitors; Platelet-derived growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (PO)
  • 21 Apr 2004 Preclinical trials in Cancer in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top